Results 1 to 10 of about 3,281 (174)

Cyclosporine A and Romiplostim as a Bridging Therapy to Curative Surgery in Aplastic Anemia Complicated by Gastric Cancer: A Case Report. [PDF]

EJHaem
ABSTRACT We present a case of aplastic anemia (AA) complicated with gastric cancer that was successfully treated with cyclosporine A (CsA) and romiplostim (ROMI) as a bridging therapy before curative surgery. This patient had untreated gastric cancer at the time of AA diagnosis, and surgery was difficult because of thrombocytopenia.
Nakagawa N, Yamazaki M, Hosokawa K.
europepmc   +2 more sources

Romiplostim for refractory chemotherapy-induced thrombocytopenia in a long-term survivor of limited-stage small cell lung cancer: a case report [PDF]

Frontiers in Oncology
BackgroundAggressive chemoradiotherapy for limited-stage small cell lung cancer (SCLC) frequently causes severe hematologic toxicities, particularly chemotherapy-induced thrombocytopenia (CIT), which can compromise treatment efficacy.
Mingfang Wang, Ping Tian, Taosheng Huang, Kai Sun, Jie Liu, Peng Wang   +5 more
doaj   +2 more sources

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials [PDF]

Br J Haematol
British Journal of Haematology, Volume 209, Issue 4, Page 1955-1959, October 2026.
Lee J, Hosokawa K, Jang J, Obara N, Sawa M, Usuki K, Oshikawa G, Kizaki M, Nagafuji K, Lin T, Hanamoto H, Mun Y, Kawakita T, Imada K, Cheong J, Park S, Tabayashi T, Gamou M, Murotani K, Yamazaki H.   +19 more
europepmc   +2 more sources

Long-term safety and effectiveness of romiplostim in patients with refractory aplastic anemia: a nationwide, all-case, post-marketing surveillance study in Japan [PDF]

Annals of Hematology
This all-case post-marketing surveillance study in Japan evaluated the safety and effectiveness of romiplostim, a thrombopoietin receptor agonist, in patients with aplastic anemia (AA), a rare disease characterized by pancytopenia.
Mitsuhiro Itagaki, Hiroshi Kuwazawa, Shun Sasaki, Moe Matsuura, Yudai Tanaka, Naoshi Obara   +5 more
doaj   +2 more sources

Comparison of the real-world efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in chemotherapy-induced thrombocytopenia [PDF]

BMC Cancer
Objective This study retrospectively compared the efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in managing chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumours, aiming to provide valuable evidence ...
Yu Cheng, Juan Wei, Fang Zhu, Liang Xuan, Yuan Li, Lei Meng, Chuandong Zhu, Huihui Zhao   +7 more
doaj   +2 more sources

Romiplostim during pregnancy in refractory primary immune thrombocytopenia: Literature review and case series [PDF]

Therapeutic Advances in Hematology
Primary immune thrombocytopenia (ITP) in pregnancy presents significant therapeutic challenges, particularly when refractory to standard treatments such as corticosteroids, intravenous immunoglobulin, and immunosuppressants.
Dina Weinstein Mezan, Efrat Shekel, Batia Roth, Yosef Kalish, Doron Kabiri   +4 more
doaj   +2 more sources

Romiplostim in the management of severe aplastic anemia: a comprehensive clinical review [PDF]

Annals of Hematology
Severe aplastic anemia (SAA) is a rare bone marrow failure disorder with high morbidity and mortality, particularly in patients ineligible for hematopoietic stem cell transplantation.
Mostafa F. Mohammed Saleh, Abdulrahman Nasiri, Ahmed Kotb, Haroon Alfadil, Hazza Alzahrani, Mahmoud Aljurf, Ali Alahmari   +6 more
doaj   +2 more sources

Comparative thromboembolic risk of romiplostim versus eltrombopag in immune thrombocytopenia: a propensity score-matched cohort study [PDF]

Annals of Hematology
Immune thrombocytopenia (ITP) is associated with both bleeding and thrombotic complications. Thrombopoietin receptor agonists (TPO-RAs), particularly romiplostim and eltrombopag, are widely used as second-line therapy, yet comparative data on ...
Anand Shah, Rajvi Gor, Joshua Kra
doaj   +2 more sources

Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia [PDF]

Yeungnam University Journal of Medicine, 2021
We report the case of a 16-month-old patient with chronic immune thrombocytopenia (ITP) patient who experienced delayed treatment-free response (TFR) after romiplostim treatment.
Hyun Ji Lim, Young Tae Lim, Jeong Ok Hah, Jae Min Lee   +3 more
doaj   +1 more source

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers

Pharmacology Research & Perspectives, 2023
Aims The pharmacodynamic (PD) similarity between GP40141, a proposed romiplostim biosimilar, and reference romiplostim was evaluated. Pharmacokinetics and safety were also assessed.
Igor Makarenko, Artem Dorotenko, Sergey Noskov, Veniamin Banko, Valeria Saparova, Alexandr Khokhlov, Evgeniia Zoreeva, Andrey Nedorubov, Bella Zinnatulina, Maria Gefen, Roman Drai   +10 more
doaj   +1 more source